Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03818295 · ClinicalTrials.gov registry record · Phase 1
A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Praliciguat in Healthy Male Volunteers
A Phase 1 study, sponsored by Cyclerion Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03818295 is a Phase 1 study that has completed, run by Cyclerion Therapeutics. The registered enrollment target is 8 participants.
The verdict
NCT03818295, a Phase 1 study, has completed, sponsored by Cyclerion Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary objective is to characterize the pharmacokinetics (PK) of praliciguat and total radioactivity and to assess the elimination of total radioactivity from a single oral dose of \[14C\]-praliciguat.
Interventions
- DRUG [14C]-praliciguat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2019-04-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03818295
The ClinicalTrials.gov registry entry for NCT03818295 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cyclerion Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C]-praliciguat is the first listed.
NCT03818295 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03818295 about?
NCT03818295 is a clinical study titled "A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Praliciguat in Healthy Male Volunteers". The primary objective is to characterize the pharmacokinetics (PK) of praliciguat and total radioactivity and to assess the elimination of total radioactivity from a single oral dose of \[14C\]-praliciguat.
What is the current status of trial NCT03818295?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2019-03-01. Estimated completion is 2019-04-24.
What interventions are being tested in trial NCT03818295?
The interventions under investigation include: [14C]-praliciguat (DRUG).
Who is sponsoring clinical trial NCT03818295?
This trial is sponsored by Cyclerion Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.